05/19/2021
11:00 am - 12:00 pm
Join us at the Dermatology Innovation Leadership Think Tank meeting featuring Christoph Ellebrecht, MD and Aimee Payne, MD, PhD, of University of Pennsylvania, as they discuss Chimeric antigen receptor (CAR) T cells as a precision curative therapy for gamma-delta T cell cancers.
The University of Pennsylvania’s successes in treating cancer with CAR T cell therapy represent two decades of investment in the people and infrastructure to advance these novel cellular immunotherapies to clinical trials. Clinician-scientists of all disciplines and in every career stage are now empowered to harness the immune system to treat more cancers, as well as other immune diseases.
Webinar Takeaways:
Who Should Attend?
About the Presenters:
Penn Medicine’s Aimee Payne, MD, PhD, continues to re-define this field. Dr. Payne is Professor of Dermatology and Director of the Penn Clinical Autoimmunity Center of Excellence at the University of Pennsylvania. She is also co-founder and co-chair of the Scientific Advisory Board at Cabaletta Bio (NASDAQ:CABA), focused on targeted cellular immunotherapies of B cell-mediated diseases. Her group invented a precision cellular immunotherapy for autoimmunity known as DSG3-CAART, which is being evaluated in a first-in-human clinical trial that launched in 2020.
Christoph Ellebrecht, MD, rising Clinical Instructor of Dermatology and co-inventor of DSG3-CAART, is now expanding CAR-T technology to create one of the few programs targeting gamma-delta T cell cancers, a rapidly lethal group of cancers notoriously refractory to current chemotherapeutic approaches. Targeting the gamma-delta T cell receptor with CAR T cells offers a potentially curative therapy for this devastating group of cancers with high unmet need for effective treatments.